December 2, 2025 Alpha Tau Receives FDA Approval to Initiate a Trial for Patients with Locally Recurrent Prostate Cancer Globe Newswire View Article
October 31, 2025 Alpha TAU Medical – Bassett Healthcare in Cooperstown is home to a national clinical trial that uses a new radiation therapy for inoperable pancreatic cancer. The Daily Star View Article
September 2, 2025 Alpha Tau Successfully Treats First Patient in its U.S. Multi-Center Pancreatic Cancer Clinical Trial Globe Newswire View Article
April 28, 2025 Alpha Tau Announces Closing of $36.9 Million Registered Direct Offering and Strategic Marketing Alliance with Oramed Pharmaceuticals View Article
April 2, 2025 Alpha Tau Receives FDA Approval to Initiate a Trial for Patients with Recurrent Glioblastoma View Article
February 3, 2025 Alpha Tau Announces FDA Approval of IDE Supplement to Expand Pilot Trial of Alpha DaRT® to Thirty Patients with Pancreatic Cancer in Two Cohorts, with Locally Advanced or Metastatic Disease View Article
January 27, 2025 Alpha Tau Announces Cornerstone Interim Data Across Multiple Clinical Trials to be Shared at R&D Update Day View Article
October 21, 2024 Alpha Tau Announces Acceptance Into FDA’s Total Product Life Cycle Advisory Program to Accelerate Market Access to Alpha DaRT® for Patients with Recurrent Glioblastoma Multiforme View Article
